Michael D. Lockshin | |
---|---|
Born |
Columbus, Ohio |
December 9, 1937
Nationality | American |
Institutions | Hospital for Special Surgery |
Alma mater | Harvard Medical School |
Known for | Autoimmune diseases |
Michael D. Lockshin, M.D., is an American professor and medical researcher. He is a researcher of autoimmune diseases, with focus on antiphospholipid syndrome and lupus. He is currently Professor of Medicine and Obstetrics-Gynecology at the Weill-Cornell University Medical College in New York City. In addition, he is Director, Barbara Volcker Center for Women and Rheumatic Disease and Co-Director, Mary Kirkland Center for Lupus Research both at the Hospital for Special Surgery
Locksin's twin brother, Richard A. Lockshin, is an American cellular biologist known for his work on apoptosis.
Michael Lockshin graduated cum laude from Harvard College in 1959 with an AB in history and literature. He received his MD in 1963 from Harvard Medical School. Lockshin interned and did his residency at Bellevue Hospital and the Memorial Sloan Kettering Cancer Center and his fellowship in Rheumatic Diseases at Columbia Presbyterian Medical Center in New York City.
Dr. Lockshin's long-term research interest is in the clinical aspects of systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), pregnancy in rheumatic disease patients, gender and rheumatic disease, and neurological SLE.
He has written three books for the general reading public. Guarded Prognosis: A Doctor and his Patients Talk about Chronic Disease and How to Cope With It (Hill and Wang, a division of Farrar, Straus and Giroux) was published in 1998. Dancing at the River’s Edge: A Patient and Her Doctor Negotiate a Life With Chronic Illness (Schaffner Press, Inc. 2009) is a personal dual memoir, written in collaboration with long-time patient Alida Brill. His latest book, The Prince at the Ruined Tower: Time, Uncertainty & Chronic Illness (Custom Databanks, Inc. 2017) explores seldom discussed issues of contemporary medical practice—how should and how do patients, doctors, insurers, and administrators respond when diagnoses are uncertain?